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Abstract
Background
Comorbidities are common in patients with heart failure (HF) and complicate treatment and
outcomes. We identified patterns of multimorbidity in Asian patients with HF and their asso-
ciation with patients’ quality of life (QoL) and health outcomes.
Methods and findings
We used data on 6,480 patients with chronic HF (1,204 with preserved ejection fraction)
enrolled between 1 October 2012 and 6 October 2016 in the Asian Sudden Cardiac Death
in Heart Failure (ASIAN-HF) registry. The ASIAN-HF registry is a prospective cohort study,
with patients prospectively enrolled from in- and outpatient clinics from 11 Asian regions
(Hong Kong, Taiwan, China, Japan, Korea, India, Malaysia, Thailand, Singapore, Indonesia,
and Philippines). Latent class analysis was used to identify patterns of multimorbidity. The pri-
mary outcome was defined as a composite of all-cause mortality or HF hospitalization within 1
year. To assess differences in QoL, we used the Kansas City Cardiomyopathy Questionnaire.
We identified 5 distinct multimorbidity groups: elderly/atrial fibrillation (AF) (N = 1,048; oldest,
more AF), metabolic (N = 1,129; obesity, diabetes, hypertension), young (N = 1,759; youn-
gest, low comorbidity rates, non-ischemic etiology), ischemic (N = 1,261; ischemic etiology),
and lean diabetic (N = 1,283; diabetic, hypertensive, low prevalence of obesity, high preva-
lence of chronic kidney disease). Patients in the lean diabetic group had the worst QoL, more
severe signs and symptoms of HF, and the highest rate of the primary combined outcome
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002541 March 27, 2018 1 / 22
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Tromp J, Tay WT, Ouwerkerk W, Teng T-
HK, Yap J, MacDonald MR, et al. (2018)
Multimorbidity in patients with heart failure from
11 Asian regions: A prospective cohort study using
the ASIAN-HF registry. PLoS Med 15(3):
e1002541. https://doi.org/10.1371/journal.
pmed.1002541
Academic Editor: Kazem Rahimi, University of
Oxford, UNITED KINGDOM
Received: October 18, 2017
Accepted: February 21, 2018
Published: March 27, 2018
Copyright: © 2018 Tromp et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data are from the
ASIAN-HF study whose authors may be contacted
at norhidayati.m.h@nhcs.com.sg.
Funding: The ASIAN-HF registry is supported by
research grants from Boston Scientific Investigator
Sponsored Research Program, National Medical
Research Council of Singapore, ASTAR
Biomedical Research Council ATTRaCT program,
and Bayer. The funders had no role in study design,
within 1 year (29% versus 11% in the young group) (p for all <0.001). Adjusting for confound-
ers (demographics, New York Heart Association class, and medication) the lean diabetic
(hazard ratio [HR] 1.79, 95% CI 1.46–2.22), elderly/AF (HR 1.57, 95% CI 1.26–1.96), ische-
mic (HR 1.51, 95% CI 1.22–1.88), and metabolic (HR 1.28, 95% CI 1.02–1.60) groups had
higher rates of the primary combined outcome compared to the young group. Potential limita-
tions include site selection and participation bias.
Conclusions
Among Asian patients with HF, comorbidities naturally clustered in 5 distinct patterns, each
differentially impacting patients’ QoL and health outcomes. These data underscore the
importance of studying multimorbidity in HF and the need for more comprehensive
approaches in phenotyping patients with HF and multimorbidity.
Trial registration
ClinicalTrials.gov NCT01633398
Author summary
Why was this study done?
• The prevalence of multimorbidity (2 comorbidities) is increasing among patients with
heart failure.
• Multimorbidity can impede survival and complicate treatment.
• Yet, previous studies have investigated single comorbidities in isolation.
What did the researchers do and find?
• Using latent class analysis, we identified patterns of multimorbidity among patients
with heart failure from 11 regions in Asia in a prospective cohort study of 6,480 patients
with heart failure (1,204 with heart failure and a preserved ejection fraction).
• We identified 5 multimorbidity groups: elderly/atrial fibrillation (old, more atrial fibrilla-
tion), metabolic (obese, diabetic, hypertensive), young (younger, low prevalence of comor-
bidities), ischemic (ischemic etiology), and lean diabetic (diabetic, low prevalence of obesity).
• Multimorbidity groups had distinct geographic distributions across Asia and were asso-
ciated with changes in cardiac structure and function.
• Overall, the lean diabetic group had the strongest association with a combined outcome
of mortality or hospitalization for heart failure.
What do these findings mean?
• Our findings suggest that multimorbidity is highly prevalent in patients with heart fail-
ure and is associated with a distinct geographic distribution and adverse outcomes.
Multimorbidity in Asian heart failure
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• Combined, our data underscore the importance of multimorbidity in patients with
heart failure and call for more comprehensive approaches in phenotyping patients with
heart failure and multimorbidity.
Introduction
Multimorbidity, the presence of 2 or more chronic medical conditions in an individual, is
highly prevalent in patients with heart failure (HF) [1–3]. Indeed, with aging populations
worldwide, patients with age-related multimorbidity are becoming the norm rather than the
exception. This is especially so in Asia, with the most rapidly aging populations in the world,
where almost two-thirds of patients with HF were found to have multimorbidity [4]. Comor-
bidities and their treatments may complicate the diagnosis, treatment, and outcomes of
patients with HF, affect patient preferences for care, and negatively impact patient outcomes.
Within the HF syndrome, we currently distinguish HF with reduced ejection fraction
(HFrEF) from HF with preserved ejection fraction (HFpEF). Early HF trials defined HF using
a reduced left ventricular ejection fraction (LVEF) as an entry criterion, leading to the distinc-
tion of HFrEF from HFpEF since large trials of medications (e.g., renin-angiotensin-aldoste-
rone system blockers) that showed improved survival in HFrEF later failed to improve
outcomes in similar trials for HFpEF [5]. Cardiac structure and function are distinct between
the HF groups: patients with HFrEF mostly display left ventricular (LV) eccentric remodeling
with systolic dysfunction, whereas patients with HFpEF more often have concentric remodel-
ing with preserved LV pump function but prominent diastolic dysfunction and increased fill-
ing pressures [6]. The underlying basis for these differences remains poorly understood and
has been postulated to be related to the different comorbidity burdens in these patients [7].
Most prior clinical research has focused on individual comorbidities in isolation and has
not studied the burden and patterns of multimorbidity in HF. Understanding how comorbidi-
ties cluster in individuals, and the impact of clustering of comorbidities on patient outcomes,
is an important step towards personalizing HF treatment approaches for better outcomes [5,8–
13].
Thus, we sought to identify the patterns and burden of multimorbidity in Asian patients
with HF, as well as the association of specific multimorbidity patterns with patients’ quality of
life (QoL), cardiac remodeling, and health outcomes. We hypothesized that comorbidities
would cluster in specific multimorbidity groups, regardless of ejection fraction, and that these
groups would differentially influence patients’ QoL, cardiac remodeling and health outcomes.
Furthermore, we hypothesized that regional variation would exist across Asia, providing
important insights for healthcare resource allocation and a tailored approach to patients from
different Asian regions.
Methods
Study design, study population, and setting
This study is reported as per the Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) guidelines (S1 Checklist). Ethics approvals were obtained from the rele-
vant human ethics committees at all sites. All patients included provided written informed
consent, and this study adheres to the principles of medical research as laid down in the Decla-
ration of Helsinki. We studied comorbidities in 6,480 HF patients enrolled (1 October 2012
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and 6 October 2016) in the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) regis-
try. The prospective study design of the ASIAN-HF registry has been published previously
[4,14]. The primary analysis described in the prospective study design related to sudden car-
diac death and utilization of implantable cardiac defibrillators in HFrEF, and the primary out-
comes have been published [15]. Subsequent publications from the ASIAN-HF registry are
guided by a publication charter and overseen by a publications committee.
In brief, the ASIAN-HF registry is a multinational registry of Asian patients with HF from
46 medical centers across 11 regions (Taiwan, Hong Kong, China, India, Malaysia, Thailand,
Singapore, Indonesia, Philippines, Japan, and Korea; S1 Table). Patients included in the
ASIAN-HF registry were all eligible patients at enrollment sites who met predetermined inclu-
sion and exclusion criteria and provided informed written consent for participation. Recruit-
ment sites were selected to include a broad spectrum of medical, cardiology, and HF specialty
units that regularly manage and follow patients with chronic HF. Patients included in the
ASIAN-HF registry were >18 years of age with symptomatic HF (at least 1 previous episode of
decompensated HF in the previous 6 months resulting in a hospital admission or treatment in
outpatient clinic). Patients with severe valvular heart disease as a cause of HF, with a life-
threatening comorbidity with a life expectancy <1 year, or unable or unwilling to give consent
were excluded. The ASIAN-HF registry was originally designed to include only patients with
HFrEF (LVEF < 40%) [4,14], but in 2013 the study underwent a protocol amendment to also
include patients with HFpEF (LVEF 50%). Recruitment of patients with HFpEF started later
than the recruitment of patients with HFrEF, for funding reasons. However, the delay was
only 1 year (1 October 2012 versus 9 September 2013), and for the majority of the recruitment
period (until 6 October 2016) there was overlap in recruitment of both types of HF. We do not
anticipate that there were substantial shifts in epidemiology or treatment of patients with
HFrEF or HFpEF during this short period of 1 year that may have biased the regional patterns
of multimorbidity groups, although the potential for bias cannot be excluded. Data on demo-
graphics, previous medical history, clinical symptoms, and functional status were collected.
According to the protocol, patients underwent standard 12-lead electrocardiography (ECG)
and transthoracic echocardiography at inclusion.
Study definitions
The definitions of comorbidities in the ASIAN-HF registry have previously been described
[4,14]. Obesity was defined according to the standard body mass index (BMI) cutoff defined
by the World Health Organization (WHO) (30 kg/m2). Coronary artery disease (CAD) was
defined as angiographically documented presence of significant coronary obstruction, history
of myocardial infarction, or prior revascularization. Hypertension was defined as any past or
current history of hypertension and treatment for hypertension. Diabetes was defined as hav-
ing a (prior) diagnosis of diabetes. Estimated glomerular filtration rate (eGFR) was calculated
using the Modification of Diet in Renal Disease Study equation, and chronic kidney disease
(CKD) was defined as eGFR< 60 ml/min/1.73 m2. Anemia was defined according to WHO
criteria: hemoglobin <13 g/dl for men and<12 g/dl for women. Atrial fibrillation (AF) was
defined as having a medical history or AF on ECG. Peripheral arterial and venous disease
(PAVD), previous stroke, chronic obstructive pulmonary disease (COPD), peptic ulcer, renal
artery stenosis, dementia, liver disease, cancer, and depression were identified by medical
history.
QoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a
23-item self-administered HF-specific questionnaire validated in multiple HF-related disease
states [16–21]. KCCQ domain scores range from 0 to 100; higher scores represent better QoL.
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Ethnicity was self-reported. Region income level was defined according to World Bank crite-
ria: low—Indonesia, Philippines, and India; middle—China, Thailand, and Malaysia; high—
Singapore, Hong Kong, Taiwan, South Korea, and Japan.
Medications by therapeutic class were identified, including angiotensin-converting enzyme
inhibitors (ACEis) or angiotensin receptor blockers (ARBs), beta-blockers, mineralocorticoid
receptor antagonists (MRAs), and diuretics. Medication use was captured at baseline.
Outcomes
The primary outcome of this study was all-cause death or HF hospitalization within 1 year. In
all, 5,875 (90.7%) patients had outcome data available, whereas 605 (9.3%) patients were lost to
follow-up. Patients with less than 1 year of follow-up available were censored at their last
known visit date. Outcomes were adjudicated by an independent committee. Secondary out-
comes were all-cause mortality alone and hospitalization for HF alone. All data were captured
prospectively in an electronic database, with registry operations and data management han-
dled by Quintiles Outcomes as the contract research organization appointed by the academic
executive committee.
Echocardiography
The collection and processing of echocardiographic data has previously been described [14].
Echocardiography was performed at each center according to internationally accepted guide-
lines [22]. LVEF, LV dimensions, left atrial dimensions, LV diastolic function, stroke volume,
and cardiac output were measured. The Cardiovascular Imaging Core Laboratory of the
National University Health System, Singapore, provided oversight and imaging protocol
guidelines as well as quality assurance of echocardiograms. Accuracy and reproducibility of
interpreted results were ensured through consistent training and systematic analytical pro-
cesses provided by the core laboratory according to international guidelines [22]. For further
calculations, LV mass (LVM) was calculated from linear dimensions and indexed to height2.7
as well as to body surface area (BSA) [22]. Relative wall thickness (RWT) was calculated by the
formula (2 × diastolic posterior wall thickness)/diastolic LV internal diameter. LV hypertrophy
(LVH) was determined as LVM indexed to BSA>115 g/m2 in men and>95 g/m2 in women
[22]. Normal cardiac geometry was defined as having no LVH and a RWT 0.42. Abnormal
cardiac geometry (cardiac remodeling) was classified as concentric remodeling (no LVH and
RWT> 0.42), concentric hypertrophy (LVH and RWT> 0.42), or eccentric hypertrophy
(LVH and RWT 0.42). Left atrial size was indexed to BSA [22].
Statistical analysis
Latent class analysis (LCA) was performed using the poLCA package in the R statistical package
[23] to identify groups of patients with patterns of comorbidities. Briefly, a comprehensive list of
comorbidities—which included AF, CAD, stroke, CKD, obesity, hypertension, COPD, peptic
ulcer, renal artery stenosis, cancer, liver disease, dementia, anemia, depression, diabetes, and
PAVD—was analyzed to identify group membership of individual patients. Maximum likeli-
hood estimations were used to identify patient groups based on multimorbidity type for a range
of 2–10 groups. The optimal number of groups was identified using the first minimum of the
Bayesian information criterion (BIC). The BIC is suggested to provide for the most parsimoni-
ous model selection and is recommended in LCA [23–25]. poLCA uses random starts; therefore,
each model was estimated with 10 replications. Cases with missing covariates were removed in
this process. In this study, the optimal number of classes was 5 (S2 Table). Patients’ individual
class membership was then derived using a Bayesian approach [23]. After determining the
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optimal number of clusters, the partial probabilities were averaged over the 10 replications.
These partial probabilities were then used to calculate each group membership in a Bayesian
fashion using the probabilities listed in S3 Table. By multiplying each probability corresponding
to each variable, a patient’s probability of belonging to a group was determined. Final group
selection was based on the patient’s highest probability of a group. Baseline echocardiographic
characteristics and KCCQ domain scores were stratified according to group membership and
are presented as means and standard deviations, medians and IQRs, or numbers and percent-
ages, as appropriate. Differences between multimorbidity groups in the entire HF cohort were
tested with 1-way analysis of variance (ANOVA), Kruskal–Wallis test, or the χ2 test, where
appropriate. We corrected for multiple testing in the tables using the Benjamini–Hochberg cor-
rection, using a false discovery rate of 0.05. In addition, we tested for interaction between group
membership and HF type (HFrEF or HFpEF) and stratified our analyses by HF type in the pres-
ence of significant interaction. For logistic regressions, the young group was used as the referent.
In logistic regression, we further corrected for age, sex, inpatient versus outpatient enrollment,
ethnicity, and New York Heart Association (NYHA) class. Kaplan–Meier curves stratified by
group membership are shown, with differences between groups tested using the log-rank test for
survival. Multivariable Cox regression analysis was used to test for differences between multi-
morbidity groups in all-cause mortality and HF-related hospitalization within 1 year, with the
young group used as a referent. We corrected for confounders selected based on clinical consid-
erations in a stepwise manner. In model 1 we corrected for age and sex. In model 2 we corrected
for variables included in model 1 and geographic zone, previous hospitalization for HF (yes/no),
NYHA class, and HFrEF versus HFpEF. In model 3 we corrected for all variables in model 2 and
usage of ACEis/ARBs, beta-blockers, MRAs, and diuretics at baseline. When analyzing HF hos-
pitalizations alone, all-cause mortality was used as a competing risk.
Prior to performing this study, we planned LCA and analyses regarding the differences
between possible multimorbidity groups for the primary combined outcome as well as differ-
ences in clinical characteristics and echocardiographic parameters and regional distribution of
multimorbidity groups. Based on recommendations during the peer-review process, we con-
ducted additional sensitivity analyses investigating the differences between multimorbidity
groups within a single ethnicity (Chinese) between 2 zones: Northeast Asia (South Korea,
Japan, Taiwan, Hong Kong, and China) and Southeast Asia (Thailand, Malaysia, Philippines,
Indonesia, and Singapore). Additionally, we included analyses of all-cause mortality alone and
hospitalizations for HF alone (with all-cause mortality as a competing risk) based on recom-
mendations from the peer-review process.
All tests were performed 2-sided, and p-values of<0.05 were considered statistically signifi-
cant. Statistical analyses were performed using STATA 13.0 (StataCorp, College Station, TX,
US) and R version 3.4.
Results
Multimorbidity groups identified by LCA
Overall, patients were on average 62 years old, and 27% were female (Table 1). Patients were
primarily of Chinese (33%) and Indian (30%) ethnicity, and the majority of patients were in
NYHA class II or III. The median number of comorbidities was 3, and 81% of patients had2
comorbidities in addition to HF. Among all comorbidities, hypertension (55%) was the most
common, followed by CAD (46%) and CKD (45%).
In the entire cohort, 5 multimorbidity groups of relatively equal size (N = 1,048–1,759)
were identified, each characterized by a different combination of comorbidities: elderly/AF,
metabolic, young, ischemic, and lean diabetic.
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Patients in the elderly/AF group, were the oldest (mean age 68.2 years), had the highest
prevalence of AF (67.6%) and stroke (19.8%), and had a comparatively high prevalence of
CKD (63.6%). They were also more likely to be of Chinese, Japanese, or Korean ethnicity and
from high-income regions.
Patients in the metabolic group had the highest mean BMI (29 kg/m2) and prevalence of
obesity (45.1%), combined with a high prevalence of hypertension (87.8%) and diabetes
(63.5%). These patients were relatively young (mean age 59.1 years), often of Malay ethnicity,
and most often on ACEis/ARBs.
Patients in the young group were the youngest (mean age 55.6 years) and had an exception-
ally low proportion of all comorbidities, with high prevalence on non-ischemic etiology of HF
(77.8%). These patients were primarily of Indian or Chinese ethnicity and from low-income
regions and were most the likely to be treated with MRAs. These patients had the lowest abso-
lute number of comorbidities (0, IQR 0,1).
Patients in the ischemic group were of intermediate age (mean age 62.4 years); this group
had the highest proportion of men (83%) compared to the other groups. Overall, these patients
were most often Indian and had ischemic etiology of HF (71%), with lower prevalence of dia-
betes (43%) compared to the young group but the highest prevalence of CAD (88%; p for all
comparisons < 0.001) and high prevalence of anemia (69%).
The lean diabetic group consisted of patients of intermediate age (mean age 66.1 years)
with a strikingly high prevalence of diabetes (97%) despite a low prevalence of obesity (22%).
They also had high prevalence of hypertension (95%), CKD (89%), anemia (78.5%), and CAD
(76%). These patients were commonly of Malay ethnicity and from high-income regions
(60%). These also appeared to be the sickest patients, with the worst signs and symptoms of
HF and frequent history of hospitalization for HF (69%). These patients had the highest abso-
lute number of comorbidities (5, IQR 5, 6).
Patients from the lean diabetic group had the worst overall QoL, while patients from the
young group had the best QoL, comparing overall summary scores (Table 2). Similarly, the
lean diabetic group had poorer QoL as compared to the young group in the domains of total
symptoms and social limitations.
Distribution of multimorbidity groups by region
The distribution of multimorbidity groups by region is summarized in Fig 1. In China and
Thailand, the young group was most prevalent (Fig 2A). In Hong Kong, the majority of
patients belonged to the lean diabetic and elderly/AF groups. Indian and Indonesian patients
most often belonged to the young and ischemic groups. Japanese and Korean patients most
often belonged to the elderly/AF and young groups. Overall, patients from Singapore and
Malaysia were in either the lean diabetic or metabolic group. Patients from the Philippines and
Taiwan were most often in the metabolic group.
We performed sensitivity testing restricted to a single ethnicity (Chinese) in 2 different
zones (Southeast Asia and Northeast Asia) and found that the same phenotypic groups
emerged in each zone, with similar characteristics within each group. This suggests that the
phenotypic groups were not simply due to ethnic or regional differences in inclusion criteria,
but may represent underlying biological differences.
Distribution of multimorbidity groups by type of HF
The relative prevalence of the ischemic and young groups was higher in HFrEF, while the
elderly/AF, metabolic, and lean diabetic groups had a higher relative prevalence in HFpEF (Fig
2B). When adjusted for age, sex, inpatient versus outpatient enrollment, ethnicity, and NYHA
Multimorbidity in Asian heart failure
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Table 1. Baseline characteristics according to multimorbidity group.
Characteristic Total cohort Multimorbidity group p-Value
Elderly/AF Metabolic Young Ischemic Lean diabetic
N 6,480 1,048 1,129 1,759 1,261 1,283
Demographics
Age, years 61.6 (13.3) 68.2 (12.4) 59.1 (12.5) 55.6 (14.3) 62.4 (11.3) 66.1 (10.8) <0.001
Female sex 1,750 (27.0%) 321 (30.6%) 302 (26.7%) 527 (30.0%) 217 (17.2%) 383 (29.9%) <0.001
Ethnicity
Chinese 2,150 (33.2%) 437 (41.7%) 423 (37.5%) 484 (27.5%) 331 (26.3%) 475 (37.0%) <0.001
Indian 1,963 (30.3%) 87 (8.3%) 317 (28.1%) 670 (38.1%) 564 (44.8%) 325 (25.3%)
Malay 973 (15.0%) 128 (12.2%) 200 (17.7%) 168 (9.6%) 190 (15.1%) 287 (22.4%)
Japanese 661 (10.2%) 220 (21.0%) 82 (7.3%) 212 (12.1%) 68 (5.4%) 79 (6.2%)
Korean 355 (5.5%) 109 (10.4%) 45 (4.0%) 121 (6.9%) 42 (3.3%) 38 (3.0%)
Thai 199 (3.1%) 41 (3.9%) 26 (2.3%) 55 (3.1%) 33 (2.6%) 44 (3.4%)
Filipino 53 (0.8%) 9 (0.9%) 13 (1.2%) 13 (0.7%) 8 (0.6%) 10 (0.8%)
Indigenous SEA 109 (1.7%) 17 (1.6%) 19 (1.7%) 31 (1.8%) 22 (1.7%) 20 (1.6%)
Other 14 (0.2%) 0 (0.0%) 3 (0.3%) 5 (0.3%) 1 (0.1%) 5 (0.4%)
County income level
Low 2,089 (32.3%) 141 (13.5%) 311 (27.5%) 753 (42.8%) 606 (48.1%) 278 (21.7%) <0.001
Middle 1,289 (19.9%) 198 (18.9%) 236 (20.9%) 375 (21.3%) 249 (19.7%) 231 (18.0%)
High 3,102 (47.8%) 709 (67.7%) 582 (51.6%) 631 (35.9%) 406 (32.2%) 774 (60.3%)
NYHA class
I 776 (13.5%) 115 (12.2%) 145 (14.6%) 214 (13.7%) 153 (13.3%) 149 (13.3%) 0.014
II 3,085 (53.5%) 512 (54.4%) 544 (54.8%) 855 (54.8%) 590 (51.2%) 584 (52.2%)
III 1,586 (27.5%) 247 (26.2%) 269 (27.1%) 400 (25.7%) 336 (29.2%) 334 (29.8%)
IV 317 (5.5%) 67 (7.1%) 35 (3.5%) 90 (5.8%) 73 (6.3%) 52 (4.6%)
Systolic blood pressure, mm Hg 121.0 (21.2) 119.7 (21.2) 126.7 (21.1) 116.7 (19.5) 116.8 (20.2) 126.9 (21.7) <0.001
Diastolic blood pressure, mm Hg 72.4 (12.6) 71.2 (13.3) 76.2 (13.4) 72.6 (12.4) 70.9 (11.7) 71.2 (12.1) <0.001
Body mass index, kg/m2 25.3 (5.3) 23.4 (3.7) 29.0 (6.6) 24.6 (5.2) 23.6 (3.2) 26.2 (5.3) <0.001
Heart rate, bpm 79.4 (16.3) 78.3 (17.0) 80.8 (16.7) 80.0 (17.3) 78.9 (14.6) 78.9 (15.6) 0.005
eGFR, ml/min/1.73 m2 65.0 (28.1) 57.1 (22.8) 77.7 (22.8) 80.5 (26.8) 64.4 (27.4) 43.1 (20.4) <0.001
Ischemic etiology 2,840 (47.2%) 339 (34.9%) 450 (43.1%) 353 (22.2%) 853 (70.8%) 845 (69.8%) <0.001
Previous HF hospitalization
No 2,182 (33.9%) 331 (31.6%) 445 (39.5%) 666 (38.5%) 414 (32.9%) 326 (25.5%) <0.001
Yes 3,777 (58.6%) 655 (62.6%) 624 (55.4%) 855 (49.4%) 766 (60.8%) 877 (68.7%)
Unknown 483 (7.5%) 61 (5.8%) 58 (5.1%) 211 (12.2%) 80 (6.3%) 73 (5.7%)
Signs and symptoms of HF
Shortness of breath at exertion 4,647 (72.0%) 733 (69.9%) 771 (68.4%) 1,268 (72.9%) 952 (75.5%) 923 (72.2%) 0.001
Shortness of breath at rest 1,107 (17.2%) 178 (17.0%) 202 (17.9%) 278 (16.0%) 206 (16.3%) 243 (19.0%) 0.21
Reduction in exercise tolerance 4,384 (67.9%) 692 (66.0%) 746 (66.1%) 1,186 (68.2%) 900 (71.4%) 860 (67.3%) 0.033
Nocturnal cough 1,118 (17.3%) 172 (16.4%) 175 (15.5%) 303 (17.4%) 219 (17.4%) 249 (19.5%) 0.12
Orthopnea 1,368 (21.2%) 223 (21.3%) 237 (21.0%) 316 (18.2%) 258 (20.5%) 334 (26.1%) <0.001
Paroxysmal nocturnal dyspnea 1,121 (17.4%) 172 (16.4%) 188 (16.7%) 289 (16.6%) 216 (17.1%) 256 (20.0%) 0.089
Angina 697 (10.8%) 95 (9.1%) 131 (11.6%) 136 (7.8%) 177 (14.0%) 158 (12.4%) <0.001
Elevated JVP 940 (14.6%) 166 (15.8%) 152 (13.5%) 173 (10.0%) 185 (14.7%) 264 (20.7%) <0.001
Peripheral edema 1,627 (25.2%) 287 (27.4%) 330 (29.3%) 294 (16.9%) 270 (21.4%) 446 (35.0%) <0.001
Plural rales 1,062 (16.5%) 168 (16.0%) 180 (16.0%) 188 (10.8%) 241 (19.1%) 285 (22.3%) <0.001
Medical history
Previous VT/VF 445 (6.9%) 111 (10.6%) 54 (4.8%) 126 (7.3%) 79 (6.3%) 75 (5.9%) <0.001
(Continued)
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class, patients in the metabolic group were more likely to have HFpEF, while patients in the
ischemic group were more likely to have HFrEF.
Differences in cardiac structure and function by multimorbidity group
Overall, the metabolic and lean diabetic groups had the highest proportions of concentric
hypertrophy, and the young group had the highest proportion of eccentric hypertrophy (Fig
3A). When correcting for age, sex, inpatient versus outpatient enrollment, ethnicity, NYHA
class, and HFrEF versus HFpEF, the ischemic group (odds ratio [OR] 0.73, 95% CI 0.61–0.87)
and lean diabetic group (OR 0.71, 95% CI 0.59–0.85) had less LVH compared to the young
Table 1. (Continued)
Characteristic Total cohort Multimorbidity group p-Value
Elderly/AF Metabolic Young Ischemic Lean diabetic
Obesity 912 (15.3%) 19 (2.0%) 448 (45.1%) 189 (11.6%) 0 (0.0%) 256 (21.6%) <0.001
CAD 2,975 (46.2%) 306 (29.2%) 405 (36.0%) 193 (11.2%) 1,102 (87.5%) 969 (75.9%) <0.001
Diabetes 2,656 (41.3%) 164 (15.6%) 716 (63.5%) 1 (0.1%) 540 (42.9%) 1,235 (96.7%) <0.001
CKD 2,312 (45.4%) 585 (63.6%) 137 (14.7%) 200 (16.1%) 442 (47.7%) 948 (89.1%) <0.001
Stroke 434 (6.7%) 207 (19.8%) 59 (5.2%) 0 (0.0%) 2 (0.2%) 166 (13.0%) <0.001
Atrial fibrillation 1,279 (19.9%) 708 (67.6%) 124 (11.0%) 200 (11.6%) 0 (0.0%) 247 (19.3%) <0.001
Hypertension 3,562 (55.4%) 683 (65.2%) 990 (87.8%) 249 (14.4%) 430 (34.1%) 1,210 (94.8%) <0.001
PAVD 203 (3.2%) 37 (3.5%) 9 (0.8%) 7 (0.4%) 30 (2.4%) 120 (9.4%) <0.001
COPD 542 (8.4%) 145 (13.8%) 105 (9.3%) 92 (5.3%) 86 (6.8%) 114 (8.9%) <0.001
Peptic ulcer 213 (3.3%) 87 (8.3%) 32 (2.8%) 3 (0.2%) 15 (1.2%) 76 (6.0%) <0.001
Renal artery stenosis 55 (0.9%) 19 (1.8%) 0 (0.0%) 0 (0.0%) 15 (1.2%) 21 (1.6%) <0.001
Liver disease 199 (3.1%) 87 (8.3%) 4 (0.4%) 42 (2.4%) 14 (1.1%) 52 (4.1%) <0.001
Cancer 216 (3.4%) 100 (9.5%) 10 (0.9%) 43 (2.5%) 2 (0.2%) 61 (4.8%) <0.001
Dementia 43 (0.7%) 24 (2.3%) 1 (0.1%) 0 (0.0%) 2 (0.2%) 16 (1.3%) <0.001
Anemia 2,066 (40.6%) 350 (40.6%) 95 (11.6%) 259 (22.0%) 575 (69.2%) 787 (78.5%) <0.001
Depression 79 (1.2%) 34 (3.2%) 6 (0.5%) 4 (0.2%) 0 (0.0%) 35 (2.7%) <0.001
Smoker 2,636 (41.0%) 464 (44.3%) 488 (43.3%) 600 (34.8%) 549 (43.6%) 535 (41.9%) <0.001
Alcohol 1,697 (26.4%) 322 (30.8%) 341 (30.3%) 456 (26.4%) 292 (23.2%) 286 (22.4%) <0.001
Number of comorbidities 3 (2, 4) 3 (3, 4) 3 (2, 4) 1 (0, 1) 3 (2, 4) 5 (5, 6) <0.001
Medications
ACEi or ARB 4,562 (73.7%) 713 (70.1%) 904 (83.2%) 1,265 (78.3%) 881 (72.1%) 799 (64.1%) <0.001
Beta-blocker 4,682 (75.7%) 774 (76.1%) 840 (77.3%) 1,224 (75.8%) 894 (73.2%) 950 (76.2%) 0.20
MRA 3,222 (52.1%) 502 (49.4%) 574 (52.8%) 1,015 (62.8%) 654 (53.5%) 477 (38.3%) <0.001
Diuretic 4,960 (80.2%) 831 (81.7%) 873 (80.3%) 1,251 (77.5%) 959 (78.5%) 1,046 (83.9%) <0.001
Laboratory tests
Potassium, mmol/l 4.2 (3.9, 4.6) 4.2 (3.9, 4.6) 4.1 (3.8, 4.5) 4.2 (3.9, 4.5) 4.2 (3.9, 4.6) 4.3 (3.9, 4.6) 0.002
Sodium, mmol/l 139 (136, 141) 139 (136, 141) 139 (136, 141) 139 (137, 141) 138 (135, 141) 138 (136, 140) <0.001
Creatinine, μmol/l 97.3 (79.6, 131.0) 106.1 (88.4, 137.0) 84.0 (70.7, 99.0) 82.0 (70.7, 97.3) 100.0 (79.6, 132.6) 138.0 (112.0, 185.0) <0.001
Data are given as mean (SD), median (IQR), or number (percent).
Significant after Benjamini–Hochberg correction using a false discovery rate of 0.05.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; bpm, beats per minute; CAD, coronary artery disease; CKD, chronic kidney
disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; JVP, jugular venous pressure; MRA,
mineralocorticoid receptor antagonist; PAVD, peripheral arterial and venous disease; NYHA, New York Heart Association; SEA, Southeast Asian; VF, ventricular
fibrillation; VT, ventricular tachycardia.
https://doi.org/10.1371/journal.pmed.1002541.t001
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group. In contrast to the young group, the elderly/AF (OR 1.91, 95% CI 1.52–2.40), metabolic
(OR 2.46, 95% CI 1.98–3.06), and lean diabetic (OR 2.59, 95% CI 2.09–3.21) groups had more
concentric remodeling after multivariable correction.
Echocardiographic data stratified by multimorbidity group and HF type (HFrEF or
HFpEF) are presented in Tables 3 and 4. To study whether multimorbidity group affected car-
diac geometry differently in patients with HFrEF and HFpEF, we studied interactions between
multimorbidity group and HF type (HFrEF or HFpEF). We observed a significant interaction
Table 2. Kansas City Cardiomyopathy Questionnaire domain scores according to multimorbidity group.
Domain Elderly/AF, N = 1,048 Metabolic, N = 1,129 Young, N = 1,759 Ischemic, N = 1,261 Lean diabetic, N = 1,283 p-Value
Physical limitation 71 (50, 92) 79 (58, 92) 75 (55, 92) 71 (50, 88) 67 (46, 88) <0.001
Symptom stability 50 (50, 75) 50 (50, 75) 50 (50, 75) 50 (50, 75) 50 (50, 75) <0.001
Symptom frequency 75 (52, 92) 75 (50, 94) 75 (56, 94) 75 (52, 92) 69 (40, 88) <0.001
Symptom burden 75 (58, 100) 83 (58, 100) 83 (58, 100) 75 (58, 92) 75 (50, 92) <0.001
Total symptom score 76 (53, 94) 77 (54, 94) 77 (58, 94) 75 (55, 92) 71 (46, 90) <0.001
Self-efficacy score 63 (50, 75) 75 (50, 88) 75 (50, 88) 75 (50, 88) 75 (50, 88) <0.001
Quality of life score 58 (42, 75) 58 (42, 83) 58 (42, 83) 58 (42, 75) 58 (33, 75) <0.001
Social limitation score 67 (31, 94) 75 (50, 100) 75 (42, 100) 69 (38, 92) 58 (25, 88) <0.001
Overall summary score 67 (49, 85) 71 (52, 86) 72 (51, 86) 69 (48, 83) 62 (42, 81) <0.001
Clinical summary score 72 (53, 90) 76 (57, 92) 76 (57, 91) 72 (54, 88) 68 (46, 85) <0.001
Significant after Benjamini–Hochberg correction using a false discovery rate of 0.05.
AF, atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002541.t002
Fig 1. Concept figure summarizing the most important findings of this study. Region sizes in the figure are not to scale. AF, atrial fibrillation; BMI, body mass index;
CAD, coronary artery disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
https://doi.org/10.1371/journal.pmed.1002541.g001
Multimorbidity in Asian heart failure
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002541 March 27, 2018 10 / 22
between multimorbidity group and HF type for both concentric remodeling (P = 0.001) and
LVH (P = 0.011). In HFrEF, the metabolic (OR 2.53, 95% CI 1.84–3.47) and lean diabetic (OR
2.39, 95% CI 1.72–3.33) groups were more likely to have concentric remodeling as compared
to the young group, after adjusting for age, sex, inpatient versus outpatient enrollment, ethnic-
ity, and NYHA class. The ischemic group was less likely to have LVH than the young group
(OR 0.65, 95% CI 0.53–0.78). In HFrEF, the young group had the highest prevalence of eccen-
tric hypertrophy, followed by the elderly/AF group. In HFpEF, the lean diabetic group had the
highest proportion of concentric remodeling (Fig 3B and 3C).
Fig 2. Bar graphs showing the distribution of multimorbidity groups across regions and HFrEF/HFpEF. By region
(A) and HFrEF versus HFpEF (B). AF, atrial fibrillation; HFpEF, heart failure with preserved ejection fraction; HFrEF,
heart failure with reduced ejection fraction.
https://doi.org/10.1371/journal.pmed.1002541.g002
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Outcomes by multimorbidity group
In the overall cohort, 1,125 (19.2%) patients experienced the primary combined outcome of
all-cause mortality or hospitalization for HF within 1 year. Regarding secondary outcomes,
564 (9.6%) patients died, and 679 (11.6%) patients were hospitalized within 1 year.
There were clear differences in the primary combined outcome between multimorbidity
groups (P< 0.001; Fig 4). Particularly, the lean diabetic group had the highest proportion of
events of the combined outcome (HF hospitalization or mortality) within 1 year (29%), while
Fig 3. Bar graphs showing cardiac geometry across multimorbidity groups. Total cohort (A), heart failure with
reduced ejection fraction (B), and heart failure with preserved ejection fraction (C). AF, atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002541.g003
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the young group had the lowest (11%). In model 3, the lean diabetic group remained associated
with the highest proportion of events of the combined outcome (hazard ratio [HR] 1.79, 95%
CI 1.46–2.22) compared to the young group (Table 5). Similarly, the elderly/AF (HR 1.57, 95%
CI 1.26–1.96), metabolic (HR 1.28, 95% CI 1.02–1.60), and ischemic groups (HR 1.52, 95% CI
1.22–1.88) had higher rates of the combined outcome than the young group. Differences in
survival remained after adjusting for systolic function (LVEF), diastolic function (E/e0), and
cardiac geometry across groups. After correcting for number of comorbidities, the predictive
power of multimorbidity group remained; here particularly the ischemic group was associated
with a higher proportion of the combined outcome (HR 1.47, 95% CI 1.08–1.99). When inves-
tigating mortality alone, the elderly/AF group had the highest hazards for dying within 1 year
(HR 1.71, 95% CI 1.26–2.32). For hospitalizations for HF, the lean diabetic group had the high-
est hazards (HR 1.99, 95% CI 1.52–2.60).
The type of HF (HFrEF or HFpEF) modified the associations of multimorbidity groups
with the primary combined outcome (Pinteraction = 0.008), such that in HFpEF, only the lean
Table 3. Echocardiographic characteristics.
Characteristic Multimorbidity group p-Value
Elderly/AF,
N = 1,048
Metabolic,
N = 1,129
Young,
N = 1,759
Ischemic,
N = 1,261
Lean diabetic,
N = 1,283
LV dimensions
LV end diastolic dimension, mm 58 (51, 66) 59 (52, 66) 61 (54, 68) 60 (55, 66) 57 (50, 63) <0.001
LV end systolic dimension, mm 48 (36, 56) 49 (36, 57) 52 (43, 60) 51 (43, 58) 46 (36, 54) <0.001
LV end diastolic volume, ml 139 (101, 192) 156 (111, 206) 174 (132, 223) 164 (128, 207) 137 (102, 179) <0.001
LV end systolic volume, ml 92 (52, 137) 104 (56, 151) 124 (84, 170) 115 (84, 154) 90 (55, 130) <0.001
LV end diastolic volume indexed to BSA,
ml/m2
88 (64, 116) 86 (63, 111) 101 (79, 128) 97 (76, 122) 79 (61, 103) <0.001
LV end systolic volume indexed to BSA,
ml/m2
60 (36, 83) 60 (39, 81) 72 (50, 97) 69 (50, 90) 53 (34, 74) <0.001
IVSD, mm 9.6 (8.0, 11.0) 10.0 (8.4, 12.0) 9.0 (8.0, 10.0) 9.0 (7.7, 10.0) 10.0 (8.2, 12.0) <0.001
PWTD, mm 9.5 (8.0, 11.0) 10.0 (9.0, 11.5) 9.0 (8.0, 10.0) 9.0 (8.0, 10.0) 10.0 (8.0, 11.0) <0.001
Relative wall thickness 0.32 (0.26, 0.40) 0.34 (0.28, 0.42) 0.30 (0.25, 0.36) 0.31 (0.26, 0.36) 0.34 (0.28, 0.43) <0.001
LV mass, g 213 (164, 276) 228 (180, 297) 225 (175, 283) 211 (174, 258) 210 (167, 264) <0.001
LV mass indexed to BSA, g/m2 132 (104, 165) 128 (100, 161) 130 (104, 164) 126 (102, 152) 122 (98, 152) <0.001
LV hypertrophy 555 (70.3%) 536 (67.4%) 919 (70.6%) 604 (63.7%) 565 (63.0%) <0.001
Concentric remodeling 183 (21.6%) 236 (26.1%) 173 (12.6%) 124 (12.4%) 263 (27.2%) <0.001
Systolic function
LV ejection fraction, percent 31 (24, 39) 31 (23, 39) 29 (23, 36) 30 (23, 35) 32 (25, 39) <0.001
Diastolic function
E wave, cm/s 81 (61, 103) 81 (62, 100) 75 (56, 96) 80 (61, 99) 88 (68, 108) <0.001
A wave, cm/s 62 (39, 83) 66 (40, 87) 59 (40, 77) 56 (35, 80) 69 (40, 87) <0.001
E0 medial, cm/s 4.8 (3.6, 6.0) 4.0 (3.3, 5.6) 4.6 (3.6, 6.0) 4.0 (3.0, 5.0) 4.0 (3.0, 5.0) <0.001
E/e0 ratio 17.1 (12.5, 23.6) 17.8 (13.4, 25.0) 15.5 (11.7, 21.2) 19.6 (14.3, 27.4) 20.3 (15.1, 27.3) <0.001
E/a0 ratio 1.1 (0.7, 2.2) 1.2 (0.8, 2.2) 1.2 (0.8, 2.1) 1.5 (0.8, 2.6) 1.3 (0.8, 2.4) <0.001
LA dimensions
LA volume, ml 80 (57, 110) 63 (41, 87) 57 (37, 83) 57 (38, 81) 67 (48, 89) <0.001
LA volume indexed to BSA, ml/m2 50 (33, 66) 35 (23, 49) 34 (20, 49) 33 (23, 46) 39 (28, 51) <0.001
Data given as median (IQR) or number (percent).
Significant after Benjamini–Hochberg correction using a false discovery rate of 0.05.
BSA, body surface area; IVSD, interventricular septal thickness in diastole; LA, left atrial; LV, left ventricle; PWTD, posterior wall thickness in diastole.
https://doi.org/10.1371/journal.pmed.1002541.t003
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diabetic group was associated with a higher proportion of the primary combined outcome
compared to the young group (HR 2.57, 95% CI 1.19–5.59) when adjusted for age, sex, geo-
graphic zone, previous hospitalization for HF, and NYHA class.
Table 4. Echocardiographic characteristics, stratified by multimorbidity groups and heart failure type.
Characteristic Multimorbidity group p-Value
Elderly/AF Metabolic Young Ischemic Lean diabetic
HFrEF
LV dimensions
LV end diastolic volume, ml 162 (126, 208) 176 (138, 228) 181 (142, 228) 171 (136, 211) 153 (121, 194) <0.001
LV end systolic volume, ml 113 (84, 154) 126 (95, 171) 130 (98, 175) 121 (94, 159) 106 (79, 142) <0.001
IVSD, mm 9.0 (8.0, 11.0) 9.7 (8.0, 11.0) 9.0 (8.0, 10.0) 9.0 (7.2, 10.0) 9.7 (8.0, 11.0) <0.001
PWTD, mm 9.0 (8.0, 11.0) 9.9 (8.6, 11.0) 9.0 (8.0, 10.0) 9.0 (8.0, 10.0) 9.5 (8.0, 11.0) <0.001
LV mass indexed to BSA, g/m2 140 (111, 171) 133 (109, 170) 133 (109, 166) 127 (105, 154) 128 (103, 157) <0.001
Relative wall thickness 0.3 (0.2, 0.4) 0.3 (0.3, 0.4) 0.3 (0.2, 0.3) 0.3 (0.3, 0.4) 0.3 (0.3, 0.4) <0.001
Systolic function
LV ejection fraction, percent 28 (22, 34) 27 (21, 34) 27 (22, 32) 28 (22, 33) 28 (23, 34) <0.001
Diastolic function
E wave, cm/s 80 (60, 103) 84 (64, 101) 75 (56, 96) 80 (62, 100) 88 (68, 106) <0.001
A wave, cm/s 59 (36, 79) 55 (34, 78) 58 (38, 76) 52 (34, 77) 59 (35, 82) 0.18
E0 medial, cm/s 4.5 (3.2, 5.6) 4.0 (3.0, 5.2) 4.4 (3.4, 6.0) 4.0 (3.0, 5.0) 4.0 (3.0, 5.0) <0.001
E/e0 ratio 17.9 (13.1, 24.3) 19.2 (14.2, 26.9) 15.8 (12.0, 21.7) 20.4 (14.5, 28.8) 21.8 (16.0, 29.8) <0.001
E/a0 ratio 1.2 (0.7, 2.3) 1.5 (0.8, 2.6) 1.3 (0.8, 2.2) 1.6 (0.8, 2.7) 1.6 (0.8, 2.8) <0.001
Atrial size
LA volume indexed to BSA, ml/m2 49.6 (32.5, 66.8) 36.5 (24.7, 49.2) 34.3 (20.2, 49.0) 33.3 (22.9, 46.9) 40.6 (29.9, 52.2) <0.001
HFpEF
LV dimensions
LV end diastolic volume, ml 88 (72, 113) 98 (77, 121) 98 (82, 137) 97 (79, 121) 89 (68, 120) 0.006
LV end systolic volume, ml 35 (26, 49) 38 (29, 50) 41 (29, 60) 38 (30, 50) 36 (26, 55) 0.057
IVSD, mm 10.0 (9.0, 12.0) 10.5 (9.7, 12.0) 10.0 (9.0, 12.0) 10.0 (9.0, 12.0) 11.0 (9.9, 12.0) 0.005
PWTD, mm 10.0 (9.0, 12.0) 10.3 (9.2, 12.0) 10.0 (9.0, 11.0) 10.0 (9.0, 11.0) 11.0 (9.0, 12.0) 0.001
LV mass indexed to BSA, g/m2 103 (84, 129) 98 (83, 120) 99 (85, 130) 105 (85, 130) 105 (86, 134) 0.62
Relative wall thickness 0.4 (0.4, 0.5) 0.4 (0.4, 0.5) 0.4 (0.3, 0.5) 0.4 (0.4, 0.5) 0.4 (0.4, 0.5) 0.016
Systolic function
LV ejection fraction, percent 60 (55, 66) 60 (56, 68) 60 (55, 62) 60 (55, 64) 60 (55, 66) <0.001
Diastolic function
E wave, cm/s 83 (63, 103) 73 (60, 95) 75 (59, 94) 78 (59, 92) 88 (68, 111) <0.001
A wave, cm/s 76 (52, 91) 84 (66, 99) 69 (54, 91) 75 (63, 93) 85 (70, 101) <0.001
E0 medial, cm/s 5.7 (4.1, 6.6) 5.0 (4.0, 6.9) 5.3 (4.3, 7.0) 5.0 (4.0, 6.3) 5.0 (4.0, 6.0) 0.084
E/e0 ratio 15.0 (11.6, 20.2) 15.0 (10.6, 19.9) 13.2 (10.0, 17.2) 14.9 (12.0, 19.4) 17.6 (14.2, 23.3) <0.001
E/a0 ratio 0.9 (0.7, 1.5) 0.8 (0.7, 1.1) 1.0 (0.8, 1.5) 1.0 (0.7, 1.3) 0.9 (0.7, 1.4) 0.036
Atrial size
LA volume indexed to BSA, ml/m2 51.2 (34.6, 63.1) 29.9 (18.3, 41.4) 32.9 (24.0, 46.9) 30.8 (21.5, 40.2) 33.4 (25.2, 46.0) <0.001
Data given as median (IQR).
Significant after Benjamini–Hochberg correction using a false discovery rate of 0.05.
BSA, body surface area; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IVSD, interventricular septal
thickness in diastole; LA, left atrial; LV, left ventricle; PWTD, posterior wall thickness in diastole.
https://doi.org/10.1371/journal.pmed.1002541.t004
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Discussion
To the best of our knowledge this study provides the first prospective multinational data on
multimorbidity patterns among Asian patients with HF. We found several interesting results.
First, rather than occurring in isolation, comorbidities naturally clustered among Asian
patients with HF and could be categorized into 5 distinct patterns: elderly/AF, metabolic,
young, ischemic, and lean diabetic. Second, different patterns of multimorbidity were associ-
ated with different underlying patterns of cardiac remodeling. Third, striking geographic dif-
ferences were observed in the distribution of multimorbidity groups across Asia. Fourth, and
most importantly, multimorbidity groups were differentially associated with the prespecified
primary combined outcome of all-cause mortality and HF-related hospitalization. These data
highlight the importance of multimorbidity in patients with HF, improve our understanding
of the role of multimorbidity in the pathophysiology of HF, and pave the way for a tailored
approach to patients with HF.
Previous studies have identified subgroups in HF using cluster analyses [10,26–28]. Ahmad
et al. reported one of the first applications of a cluster analysis to identify clinical phenotypes
of patients with HFrEF in the HF-ACTION study [10]. Based on clinical characteristics includ-
ing ECG data, biomarkers (NT-proBNP), and signs and symptoms of HF, the authors identi-
fied 4 groups: a young group with high BMI, an elderly group with high rates of comorbidities,
an ischemic cardiomyopathy group, and a non-ischemic cardiomyopathy group [10]. How-
ever, this study included only patients with HFrEF, and only patients from a single clinical
trial, which predominantly included white men with ischemic cardiomyopathy. Similar studies
have been performed in HFpEF patients alone [28,29], with similar subgroup findings. Based
on the selected variables, these prior studies have been postulated to classify patients predomi-
nantly based on HF severity, with differences in survival driven mainly by differences in age
and NT-proBNP [30]. Another study, by Lee et al., investigated comorbidity profiles in
Fig 4. Kaplan–Meier curve showing differences for the primary combined outcome of all-cause mortality and HF-
related hospitalization within 1 year across multimorbidity groups. AF, atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002541.g004
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hospitalized HF patients using ICD codes in a US nationwide database [31]. The authors
found a lifestyle profile, with high rates of diabetes and obesity, a renal profile, with high rates
of renal disease and hypertension, a neurovascular profile (hypertension plus cerebrovascular
disease), and a common group (high rate of hypertension). The hypertensive (common group)
patients comprised the highest proportion (47%) among patients hospitalized for HF in the
US, while the renal patients comprised the second highest proportion (30%), followed by the
lifestyle (20%) and neurovascular (4%) patients with HF. This study relied on data from the
Nationwide Inpatient Sample (NIS) database, and the depth of investigation was limited by the
quality and detail of data collected [31].
Our study extends the prior literature by providing data on multimorbidity patterns and
their echocardiographic correlates and association with QoL, mortality, and hospitalization for
HF, in a large, well-characterized multinational Asian cohort of patients with HFrEF and
HFpEF. We found novel multimorbidity patterns unique to Asia such as the lean diabetic
group. Most noteworthy in our study was the prominence of the lean diabetic group in South-
east Asia (particularly Malaysia and Singapore). This was surprising given the rise in obesity in
this zone [32]. Southeast Asia is home to a rapidly growing population of>600 million people,
and is notable for its rapid epidemiological transition from “the age of receding pandemics” to
“the age of degenerative and man-made disease” and now “the age of declining cerebrovascu-
lar mortality, ageing, lifestyle modifications, and resurgent diseases” [33,34] within the genera-
tion of adults now presenting with HF. The thrifty gene hypothesis [35] may explain the
extraordinarily high rates of diabetes as a risk factor for HF in spite of the absence of overt
Table 5. Results of Cox regression analysis across multimorbidity groups for the combined outcome of all-cause mortality and hospitalization for heart failure, all-
cause mortality alone, and hospitalization for heart failure alone.
Outcome and multimorbidity group Cases/N Hazard ratio (95% CI)
Univariable Model 1 Model 2 Model 3
Combined outcome
Young 177/1,580 Ref Ref Ref Ref
Elderly/AF 211/943 2.17 (1.78–2.65) 2.11 (1.71–2.60) 1.58 (1.27–1.96) 1.57 (1.26–1.96)
Metabolic 170/1,037 1.52 (1.23–1.87) 1.50 (1.21–1.85) 1.26 (1.01–1.57) 1.28 (1.02–1.60)
Ischemic 229/1,122 1.89 (1.56–2.31) 1.80 (1.48–2.21) 1.53 (1.24–1.89) 1.51 (1.22–1.88)
Lean diabetic 338/1,185 2.89 (2.41–3.47) 2.83 (2.34–3.41) 1.89 (1.54–2.32) 1.79 (1.46–2.22)
All-cause mortality
Young 96/1,580 Ref Ref Ref Ref
Elderly/AF 115/943 2.11 (1.61–2.77) 1.98 (1.49–2.63) 1.68 (1.24–2.26) 1.71 (1.26–2.32)
Metabolic 66/1,037 1.05 (0.77–1.44) 1.02 (0.74–1.40) 0.88 (0.63–1.22) 0.88 (0.62–1.24)
Ischemic 127/1,122 1.89 (1.45–2.46) 1.77 (1.35–2.33) 1.35 (1.01–1.80) 1.34 (1.01–1.80)
Lean diabetic 159/1,185 2.34 (1.81–3.01) 2.21 (1.70–2.88) 1.52 (1.14–2.02) 1.42 (1.06–1.92)
Hospitalization for heart failure
Young 97/1,580 Ref Ref Ref Ref
Elderly/AF 127/943 2.30 (1.77–3.00) 2.32 (1.76–3.03) 1.51 (1.14–2.01) 1.47 (1.11–1.96)
Metabolic 113/1,037 1.83 (1.39–2.39) 1.81 (1.38–2.37) 1.46 (1.10–1.93) 1.46 (1.10–1.93)
Ischemic 125/1,122 1.83 (1.40–2.39) 1.77 (1.35–2.31) 1.63 (1.23–2.16) 1.60 (1.20–2.12)
Lean diabetic 217/1,185 3.23 (2.54–4.11) 3.25 (2.56–4.13) 2.07 (1.60–2.68) 1.99 (1.52–2.60)
Model 1 adjusted for age and sex. Model 2 adjusted for model 1 variables plus geographic zone, previous hospitalization for HF, NYHA class, and HF type (heart failure
with preserved ejection fraction or heart failure with reduced ejection fraction). Model 3 adjusted for model 2 variables plus beta-blockers, angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers, diuretics, and mineralocorticoid receptor antagonists.
AF, atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002541.t005
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obesity. Indeed, previous studies have shown that the prevalence of diabetes among Asian indi-
viduals is far greater than among white individuals and that diabetes occurs on average at a far
lower BMI [36]. Furthermore, diabetes is associated with higher rates of mortality and hospi-
talization for HF in Asian patients with HF than in white patients with HF. Here we showed
that among Asian patients with HF, the lean diabetic phenotype was associated with the high-
est rates of the primary combined outcome, with more than twice as many deaths or hospitali-
zations for HF compared to the young group. This is potentially driven by the high proportion
of CKD in these patients, which is a strong determinant of mortality and hospitalizations [37].
Of note, the lean diabetic patients experienced higher rates of the primary combined outcome
compared to obese diabetic patients in the metabolic group.
In Asia, the healthcare topography in terms of government health expenditure, availability
of universal health insurance coverage, and reliance on private payment varies greatly, and this
may contribute to disparities in care across the region. For instance, we have previously shown
that there was enormous variation in utilization of implantable cardiac defibrillators in eligible
patients in our cohort, which was associated with geographic variations in out-of-pocket health
expenditure and total government health expenditure [15]. The extent to which these factors
may have contributed to the regional differences in multimorbidity phenotypes and differ-
ences in all-cause mortality and hospitalization for HF warrants further study. Given that
genetic background may be determined by ethnicity [38], future studies are warranted to
determine possible genetic factors underlying the predominance of particular multimorbidity
groups in different ethnicities.
Comorbidities are associated with certain pattern of cardiac structural and functional
changes in HF [39]. Previous studies have shown that single comorbidities such as CKD, dia-
betes, and obesity affect cardiac structure and function both in patients with HF and in the
general population [39–42]. Furthermore, a greater burden (number) of comorbidities is asso-
ciated with indices of cardiac mechanics [43]. However, prior studies did not examine the
cumulative effect of specific combinations of comorbidities. The prospective design of our
study, with standardized echocardiography by protocol, enabled our detailed interrogation
into cardiac structural and functional changes that potentially underlie the different clinical
behaviors of patient groups. We found an expected association between the metabolic group
and HFpEF, as well as between the ischemic group and HFrEF. More surprising was the asso-
ciation of the lean diabetic group with the greatest extent of concentric remodeling, LVH, and
diastolic dysfunction, even more so than in the obese diabetic metabolic group in HFpEF, thus
offering a potential explanation for the higher rates of the primary combined outcome seen in
the lean diabetic group. Importantly, this provides clinical evidence of cardiometabolic distur-
bance as a key driver of cardiac dysfunction, apart from the confounding influence of weight
gain per se, and supports the recent development of drugs targeting cardiometabolic pathways
in HF [44]. In fact, our data suggest that these cardiometabolic agents may have unique appli-
cation in specific Asian populations, as opposed to weight loss as a therapeutic strategy in
Western populations [45]. Surprising was the association of the young group with the greatest
prevalence of eccentric hypertrophy, even more so than the ischemic group in HFrEF, and
despite the relative youth and strikingly low prevalence of comorbidities of individuals in the
young group.
Our findings carry implications for clinical surveillance and management of patients with
HF in different regions of Asia, as well as for design of global clinical trials in HF. This study
shows that comorbidities in patients with HF cluster into distinct multimorbidity groups that
affect mortality and hospitalization for HF beyond the sum of their parts. Future studies
should take the combinations of comorbidities into account, which could drive decisions in
personalized patient care based on survival as well as time to hospitalization for HF.
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Furthermore, patients from Southeast Asia with diabetes, even in the absence of obesity, war-
rant surveillance for HFpEF, and trials targeting HFpEF may enrich their populations by
including lean diabetic patients from the region.
Strengths and limitations
We acknowledge potential bias in site selection and willingness of patients to participate in a
prospective registry, particularly across a huge geography of 11 regions, with disparate health-
care systems at different stages of evolution [15]. Site selection in the ASIAN-HF registry was
based on the size of the region, geographic location of the site within the region, patient popu-
lation served, HF patient volume, and availability of expertise in echocardiography. Screening
logs were encouraged but not available from all sites. Nevertheless, every effort was made to
ensure protocol adherence and standardization, including language translations specific to
each region, on-site investigator training, regular monitoring (both in person and remote),
and centralized database management. The representativeness of the ASIAN-HF registry has
been discussed previously [4]. There is a paucity of multinational data on patients with HF in
Asia. Therefore, we can only rely on comparisons to single-center studies or studies reporting
on only a few countries in Asia. Previous results have shown that data on patients in the
ASIAN-HF registry are consistent with prior reports from single Asian nations [46–50]. This
suggests that patients included in ASIAN-HF registry are representative of patients with HF in
the region. Although our cohort was prospectively enrolled and followed up, we included prev-
alent HF cases and their risk factors at baseline, with the potential for survival bias and reverse
causality. For instance, the fact that the highest risk of the primary combined outcome was in
the lean diabetic group may have been because these patients were frailer or had lost weight in
the months leading up to inclusion. Of note, baseline severity of HF as measured by NYHA
class was similar between the ischemic and metabolic groups. Nonetheless, while every effort
has been made to correct for potential confounders in survival analyses, some unmeasured fac-
tors might have influenced differences in survival between groups. Particular strengths of this
study include the prospective design, uniform comprehensive data collection, detailed echo-
cardiographic characterization, and close follow-up with independent adjudication of out-
comes. We also used state-of-the-art statistical methods: LCAs are hypothesis generating and
provide us with potential new insights into multimorbidity profiles of patients with HF.
Conclusion
These first prospective multinational data on multimorbidity patterns among Asian patients
with HF showed that comorbidities naturally clustered in 5 distinct groups: elderly/AF, meta-
bolic, young, ischemic, and lean diabetic. Different multimorbidity groups were associated
with different underlying patterns of cardiac remodeling, and were differentially related to the
primary combined outcome of all-cause mortality and hospitalization for HF, as well as to the
secondary outcomes of all-cause mortality alone and hospitalization for HF alone. Striking
geographic differences were observed in the distribution of multimorbidity groups across
Asia. These data underscore the importance of multimorbidity in patients with HF and the
need for more comprehensive approaches in phenotyping patients with HF and
multimorbidity.
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